Hurd D D
Department of Medicine, University of Minnesota, Minneapolis 55455.
Semin Oncol. 1987 Dec;14(4):407-15.
Current results show that 50% of young patients with ANLL who undergo allogeneic BMT experience prolonged DFS and may be cured. Encouraging results with high-dose chemo/radiotherapy and autologous BMT are likewise being reported. In addition, some studies using intensive postremission treatment without BMT have shown results comparable to many transplant series. As better ways of preventing GVHD are found, the morbidity and mortality of allogeneic BMT should be reduced and the benefits of transplantation for curing patients with ANLL should be increased. However, the applicability of allogeneic BMT will remain limited due to the availability of compatible donors whether related or unrelated. Further studies are needed in the use of postremission intensive therapy with and without autologous bone marrow support. However, results to date should engender the same degree of enthusiastic optimism that followed the early reports of improved outcome with allogeneic BMT when applied to first remission patients.
目前的结果显示，接受异基因骨髓移植的急性非淋巴细胞白血病（ANLL）年轻患者中有50%经历了长期无病生存期（DFS），并且可能被治愈。同样也有关于高剂量化疗/放疗及自体骨髓移植的令人鼓舞的结果报道。此外，一些使用缓解后强化治疗而非骨髓移植的研究显示出与许多移植系列相当的结果。随着发现更好的预防移植物抗宿主病（GVHD）的方法，异基因骨髓移植的发病率和死亡率应会降低，而移植治愈ANLL患者的益处将会增加。然而，由于相关或无关的匹配供体的可获得性，异基因骨髓移植的适用性仍将受限。对于在有或没有自体骨髓支持的情况下使用缓解后强化治疗仍需进一步研究。不过，迄今为止的结果应能带来与早期关于异基因骨髓移植应用于首次缓解期患者时预后改善的报道之后所产生的同等程度的热情乐观情绪。
